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Extracellular chaperones
Abstract
The maintenance of the levels and correct folding state of proteins (proteostasis) is a fundamental
prerequisite for life. Life has evolved complex mechanisms to maintain proteostasis and many of these
that operate inside cells are now well understood. The same cannot yet be said of corresponding
processes in extracellular fluids of the human body, where inappropriate protein aggregation is known to
underpin many serious diseases such as Alzheimer's disease, type II diabetes and prion diseases. Recent
research has uncovered a growing family of abundant extracellular chaperones in body fluids which
appear to selectively bind to exposed regions of hydrophobicity on misfolded proteins to inhibit their
toxicity and prevent them from aggregating to form insoluble deposits. These extracellular chaperones
are also implicated in clearing the soluble, stabilized misfolded proteins from body fluids via receptormediated endocytosis for subsequent lysosomal degradation. Recent work also raises the possibility that
extracellular chaperones may play roles in modulating the immune response. Future work will better
define the in vivo functions of extracellular chaperones in proteostasis and immunology and pave the way
for the development of new treatments for serious diseases.
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1 Introduction
It has been estimated that about 400 grams of protein are synthesized and
degraded each day in the human body. Individual proteins are degraded at extremely varied rates, with half-lives ranging from several minutes to many
hours. Intracellularly, this variation in half-life has been attributed to differences in the intrinsic stability of proteins and the recognition of non-native
structures by highly selective and precisely regulated protein quality control
systems. Molecular chaperones have been identified as key players in orchestrating the control of protein folding, but almost all previous studies have
been restricted to a focus on intracellular events. The average 70 kg human
contains 15 liters of extracellular fluids, including five liters of blood. Although the concentration of proteins is lower in extracellular than intracellular
fluids (6% in plasma and 2% in interstitial fluid, 30% in cytosol), extracellular conditions are more oxidizing [1]. In addition, uniquely, extracellular fluids are continuously subjected to shear stress (e.g. the pumping of fluids
around the body) which is known to induce protein unfolding and aggregation
[2]. The relatively harsh extracellular conditions suggest that mechanisms to
sense and control the folding state of extracellular proteins are likely to be essential for the maintenance of human (and other large animal) life.
Uncontrolled protein unfolding or misfolding and the consequent accumulation of protein aggregates are implicated in the pathology of many diseases
collectively known as Protein Deposition Diseases (PDD). PDDs are typically
late-onset [3], suggesting that the underlying cause of the disease may be disruption or overwhelming of protein folding quality control mechanisms that
were once able to maintain existing proteins in their native conformation. Although the reasons for the progressive impairment of fundamental physiological processes in aging is not fully understood, it is likely that the combination
of declining protein folding quality control and exposure to thermal, ionic,
heavy metal or oxidative stress may be responsible for late-onset PDDs. All
PDDs involve protein misfolding leading to the deposition in tissues of insoluble protein aggregates; however, the type of aggregate formed varies between
the individual diseases. In many PDDs including Alzheimer’s disease, type II
diabetes, systemic amyloidosis and transmissible spongiform encephalitis, proteins deposit as highly ordered, β-sheet-rich fibrillar aggregates known as amyloid. In other PDDs the nature of the protein deposits is fibrillar, but not amyloid – for example, Lewy bodies, which are found in Parkinson’s and
Alzheimer's disease. In still other PDDs, amorphous (unstructured), nonfilamentous extracellular aggregates are formed. For example, such aggregates
are formed by IgG light chain and/or IgG heavy chain in non-amyloidotic
monoclonal IgG deposition disease (NAMIDD) [4]. In addition, drusen are
amorphous extracellular deposits that accumulate in patients with age-related
macular degeneration. In healthy eyes drusen are not found in the macula,
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however they may exist in the retinal periphery and their size and number are
considered a risk factor for developing age-related macular degeneration later
in life [5].
It is notable that many PDDs are associated with extracellular protein deposits. Thus the previous near-exclusive focus of studies on intracellular processes to control protein folding may not provide the knowledge needed to
treat these diseases. Intracellular chaperones (e.g. Hsp70 & Hsp90) may be released from necrotic [6] or apoptotic [7] cells, during viral cell lysis, secreted
in exosomes [8, 9], or via other specific mechanisms [10-12]; they have been
discovered in human plasma and associated with cell surfaces, in particular
cancer cells. Numerous extracellular roles have been postulated for these
chaperones, such as cancer cell invasiveness [13] and immune presentation
[14-21]. These “moonlighting” functions for normally intracellular chaperones may be very important. However, the low abundance of this class of
chaperone in extracellular fluids makes it unlikely that they can play a major
role in controlling the folding state of abundant extracellular proteins in body
fluids.
It has only recently become apparent that abundant extracellular counterparts to the intracellular molecular chaperones exist. Clusterin was the first
abundant extracellular chaperone (EC) to be identified [22, 23] but the number of known ECs continues to grow and now includes at least 7 members.
This Chapter outlines properties of each of the proteins that may function as
mammalian ECs, and proposes a model for how they act as key elements in a
system to monitor and control the folding state of extracellular proteins. The
model presented will also propose how the ECs may play important complementary roles in the immune system.

2 Abundant Extracellular Chaperones
There are seven currently known abundant extracellular proteins likely to function
as chaperones (outlined in table 1). The strength of the available evidence for this
varies with each protein. For more detailed information see the corresponding sections below.

Table 1: Overview of the currently known extracellular chaperones

Chaperone

Abundance

Chaperone
function

Clusterin

35-105 µg/ml (blood plasma)
1.2-3.6 µg/ml (CSF)
2-15 mg/ml (seminal plasma)

Holdase-type chaperone
activity similar to the
small heat shock proteins

α2-macroglobulin

1.5-2 mg/ml (blood plasma)
1-3.6 µg/ml (CSF)

Holdase-type chaperone
activity similar to the
small heat shock proteins

Haptoglobin

0.3-2 mg/ml (blood plasma)
0.5-2 µg/ml (CSF)

Holdase-type chaperone
activity similar to the
small heat shock proteins

Apolipoprotein E

4-6.4 µg/ml (blood plasma)
1.8-5.7 µg/ml (CSF)
40 µg/ml (blood plasma)
8.5 ng/ml (CSF)

Stabilizes proteins in
solution
ATP-independent refolding activity

~ 80% of milk protein

αS1- and β-casein have a
holdase-type chaperone
activity similar to the
small heat shock proteins
Stabilizes proteins in

Serum Amyloid P
Component
(SAP)
Caseins

αEC-Fibrinogen

2-4.5 mg/ml (blood plasma)

Disease association

References

* Associated with extracellular deposits tested including age related
macular degeneration, Creutzfeldt-Jakob disease, atherosclerosis,
Alzheimer’s disease
* Upregulated in experimental models of stress
* Genetic association with Alzheimer’s disease
* Promotes phagocytosis of pathogen Trypanosoma cruzi
* Associated with extracellular deposits in Alzheimer’s disease, dialysis related amyloidosis and Creutzfeldt-Jakob disease
* Able to stimulate a cytotoxic T lymphocyte response against chaperoned peptides
* Upregulated during infection, neoplasia, trauma, and other inflammatory conditions
* Co-deposits with amyloid in senile plaques, drusen with age-related
macular degeneration and in protein deposits associated with chronic glomerulonephritis
* Strong genetic association with Alzheimer’s disease
* Co-localizes with Alzheimer’s and Creutzfeldt-Jakob plaques
* Binds with high specificity to amyloid and is universally found in
amyloid deposits
* Elevated SAP levels in CSF of Alzheimer’s patients
* Associated with amyloid-like deposits in mammary tissue

[22-54]

[26, 91-103]

* Plasma levels are elevated under periods of stress

[104-106]

[55-65]

[66-74]

[75-81]
[82-90]
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2.1 Clusterin
Clusterin (also known as apolipoprotein J, sulfated glycoprotein 2 and SP-40,
40) was the first normally secreted protein identified as an abundant extracellular
chaperone [22]. This heat-stable glycoprotein has an extremely broad biological
distribution and exhibits high sequence homology (70-80%) across a wide range
of mammalian species, suggesting that it performs a fundamentally important
function in vivo [107]. Clusterin has been detected in all extracellular fluids that
have been tested. In humans, clusterin is present in the range of 35-105 µg/ml in
blood plasma [24], 1.2-3.6 µg/ml in cerebral spinal fluid (CSF) [25], and 2-15
mg/ml in seminal plasma [25]. Determining the biological importance of clusterin
has been complicated by the propensity of the protein to interact with a large
number of structurally diverse molecules. It is likely that many of these interactions result from a single underlying property of clusterin, which is relevant to its
primary function. Regardless, many alternative biological functions for clusterin
have been proposed including roles in lipid transport [108], sperm maturation
[109], complement regulation [107], membrane recycling [110] and apoptosis
[111].
Clusterin is encoded by a single gene and the translated product is internally
cleaved to produce two subunits, α and β, prior to secretion from the cell. Matrixassisted laser desorption ionization mass spectrometry has identified two primary
forms of human plasma clusterin at about 58 kDa and 63.5 kDa, which are likely
to be different glycoforms [112]. Approximately 17-27% of the mass of clusterin
is comprised of branched, sialic acid-rich, N-linked carbohydrates [112]. This high
carbohydrate content in addition to a high level of disorder and a tendency to form
oligomers has impeded structural analysis of clusterin, however, sequence analysis
has allowed for the prediction of several structural elements. These include three
predicted amphipathic α-helices (residues 173–184, 234–250 and 424–441) [108]
and two predicted coiled-coil helices (residues 40-99 and 318-350) [113]. The five
predicted α-helical regions are thought to be significant in the chaperone activity
of clusterin. It has been proposed that the α–helical regions form a molten globule-like binding pocket that is the site of interaction for a variety of ligands [114].
Many reports have suggested that clusterin may have intracellular importance,
for example in DNA repair [115], transcription [116], microtubule organization
[117], or apoptosis [115, 118, 119]. Various mechanisms have been proposed to
explain the presence of clusterin in intracellular compartments. This includes the
reuptake of secreted clusterin back into the cytosol [117], retrotranslation of
clusterin from the golgi to the cytosol [120], and the generation of nuclear
isoforms via alternative initiation of transcription to yield a 43 kDa isoform [121]
or via alternative splicing to yield a 49 kDa isoform [122]. Given that none of these latter studies sequenced the intracellular clusterin, it is unknown whether the
putative “isoforms” are indeed the result of alternative transcription initiation or
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splicing or whether they simply represent clusterin at different stages of maturation (e.g., cleaved or uncleaved, at different stages of glycosylation). Unambiguous structural identification of these intracellular isoforms of clusterin is required
before their existence can be firmly accepted and their function(s) meaningfully
assigned.
2.1.1 In Vitro Chaperone Activity
The hypothesis that clusterin may function as a molecular chaperone was first
proposed over 10 years ago [22]. Since that time many studies have shown that
clusterin has chaperone activity similar to that of the small heat-shock proteins
(sHsps) [22, 23, 26-29, 33]. At substoichiomentric concentrations, clusterin inhibits the stress-induced amorphous aggregation of a large number of unrelated client
proteins by binding, in an ATP-independent manner, to areas of exposed hydrophobicity on partially unfolded intermediates [22, 26-29, 31]. While clusterin
alone has no refolding activity, it can preserve heat-stressed enzymes in a state
competent for subsequent ATP-dependent refolding by Hsc70 [112]. The chaperone activity of clusterin involves the sequestration of client proteins into soluble
high molecular weight (HMW) complexes; when generated in vitro, these complexes have diameters of 50 - 100 nm and are ≥ 4 x 107 Da [31]. The maximum
“loading” of clusterin appears to correspond to a mass ratio of 1:2
(clusterin:client) regardless of the client protein [31]. Immunoaffinity depletion of
clusterin renders proteins in human plasma more susceptible to aggregation and
precipitation [27]. Fibrinogen, ceruloplasmin and albumin are major endogenous
clients for clusterin when human plasma is subjected to physiologically relevant
stress [30]. However, the method used to detect endogenous clients is biased towards those proteins that are relatively less stable and more abundant; it is likely
that clusterin acts globally to stabilize a very broad range of clients in vivo.
The chaperone activity of clusterin is not limited to those proteins that form
amorphous aggregates. Clusterin also inhibits the fibrillar aggregation of a large
number of amyloid forming clients including amyloid β (Aβ) peptide [34, 35],
PrP106–126 [36], apolipoprotein C-II [37], disease-associated variants of lysozyme [33], α-synuclein, calcitonin, κ-casein, SH3 and CCβw [32]. While clusterin
appears to prevent amyloid formation in a dose dependent manner, in some cases
very low levels of clusterin (relative to client protein) significantly increased amyloid formation [32]. It was proposed that when present at very low concentrations,
clusterin may stabilize prefibrillar oligomers that “seed” fibril growth and are believed to be primarily responsible for amyloid-associated cytotoxicity. Thus, the
clusterin:client protein ratio is an important determinant of the effects of clusterin
on amyloid formation and toxicity. It is unknown exactly how clusterin is able to
interfere with amyloid formation although the existing evidence suggests that it interacts predominantly with prefibrillar oligomeric species formed during the early
stages of amyloid aggregation [32, 33]. These early aggregating species possess
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surface-exposed hydrophobicity [123], thus the interaction of clusterin with amyloid-forming proteins may, as in the case of amorphously aggregating proteins,
arise from hydrophobic interactions.
A number of investigations have focused on identifying possible interactions
between members of the LDL receptor superfamily and clusterin [124-131]. Cellular internalization of clusterin via the LDL receptor megalin was the first reported
clusterin-LDL receptor superfamily interaction [124]. Subsequent reports described the internalization of free clusterin and clusterin-Aβ peptide complexes by
the same receptor [125, 126]. Recently, two other human members of the LDL receptor superfamily, ApoE receptor 2 and very low density lipoprotein receptor,
were reported to bind and internalize free clusterin and leptin-clusterin complexes
using transfected cell models [131]. Interactions of clusterin with chicken oocytespecific LDL receptors have also been described [128]. A recent study has suggested that megalin and LRP are capable of mediating the clusterin-dependent
clearance of cellular debris into non-professional phagocytes [129]. However, the
previous report of Kounnas et al. (1995) indicated that megalin, but not LRP,
binds clusterin. Additional unidentified mechanisms of clusterin-dependent internalization were also suggested by Bartl et al. (2001). The affinity of clusterin
binding to megalin is increased by the association of clusterin with lipids [127]. It
is currently unknown how binding interactions with other molecules, such as
stressed chaperone client proteins, affect the binding affinity of clusterin for
megalin or other members of the LDL receptor superfamily. However, it has been
shown that clusterin has independent binding sites for megalin, stressed proteins
and unstressed ligands [130].
2.1.2 Evidence for In Vivo Chaperone Action/Disease Involvement
Clusterin is found associated with extracellular protein deposits in numerous
diseases including in normal peripheral drusen and drusen in age-related macular
degeneration patients [38], with membrane attack complex in renal immunoglobulin deposits [39], in prion deposits in Creutzfeldt-Jakob disease [40, 41], with PEX
material in pseudoexfoliation (PEX) syndrome [42], in atherosclerotic plaques
[43] and in amyloid plaques or with soluble Aβ peptide in Alzheimer’s disease
[44, 45]. Two genome wide studies have recently implicated certain single nucleotide polymorphisms in the clusterin gene as risk factors for Alzheimer’s disease
[53, 54]. The overexpression of clusterin has been reported in a diverse range of
renal and neurodegenerative diseases in addition to cancers, atherosclerosis and
diabetes [46]. Additionally, clusterin is upregulated in experimental models of
pathological stress including oxidative stress [47], shear stress [48], proteotoxic
stress (generated by inhibition of the proteasome) [49], heat stress [50], ionizing
radiation [51] and exposure to heavy metals [52].
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In clusterin knock-out mice, damage to testicular cells is increased after heatshock and the removal of damaged cells is impaired [132]. After myosin-induced
auto-immune myocarditis, cell damage is also more severe in clusterin-deficient
mice [133] and post-ischemic brain injury is more severe [134]. Together this data
suggests that stress-induced increase in clusterin expression is a cytoprotective response. In an Alzheimer’s disease model, compared to control mice, mice in
which the clusterin and ApoE genes were knocked out showed early disease onset
and a marked increase in Aβ peptide levels and amyloid formation. The researchers concluded that apoE and clusterin work synergistically to inhibit the deposition
of fibrillar Aβ [135]. A more recent study has demonstrated that clusterin knockout mice develop progressive glomerulopathy which is characterized by the accumulation of insoluble protein deposits in the kidneys [136]. This directly implicates clusterin in the clearance of potentially pathological aggregating proteins,
although the precise mechanism underlying this has yet to be described.
2.2 α2-Macroglobulin (α2M)
α2M is a large secreted glycoprotein, assembled from four identical 180 kDa
subunits into a 720 kDa tetramer; disulphide linked dimers of the individual 180
kDa subunits interact non-covalently to form the final tetrameric quaternary structure [137]. The secreted molecule is comprised of ~ 10% carbohydrate by mass. It
is synthesized mainly in the liver, but is secreted from a range of different cell
types (such as astrocytes) and can be found in human plasma and cerebrospinal
fluid at 1500-2000 [56] and 1-3.6 µg/ml [57], respectively. It is best known for its
ability to inhibit a broad spectrum of proteases, which it accomplishes using a
unique trapping method. α2M contains a ‘bait region’ which undergoes limited
proteolysis upon encountering a protease, resulting in a large conformational
change and exposure of a thiol ester bond. The protease forms a covalent linkage
with α2M by reacting with the intramolecular thiol ester bond, which leads to further conformational changes exposing a receptor recognition site for low density
lipoprotein receptor related protein (LRP). Overall, these structural changes produce a more compact molecule (known as “activated” or “fast” α2M) and inhibits
the protease by physically trapping it within a steric “cage” [56]. By directly interacting with the thiol ester bond, small nucleophiles such as methylamine can also
activate α2M [138]. Although human α2M is best known for its protease inhibitor
function, it has also been shown to bind to and promote clearance of other endogenous and exogenous molecules, consistent with a broader protective function.
α2M is known to bind to cytokines and growth factors (without converting to activated α2M), including transforming growth factor-β (TGF-β), tumor necrosis factor-α (TNF-α), interleukin 1β (IL-1β), interleukin 8 (IL-8), platelet derived
growth factor-BB (PDGF-BB), nerve growth factor-β (NGF-β), and vascular endothelial growth factor (VEGF) (reviewed in refs [139, 140]). The affinity of α2M
for most cytokines is higher in the activated state, and while in this state α2M can
deliver them via receptor mediated endocytosis to lysosomes for degradation
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[141]. In addition, α2M has been shown to bind to the pathogen Trypanosoma
cruzi and promote its phagocytosis [142]. α2M has also been found to bind to endogenous proteins found in proteinaceous deposits associated with disease. α2M is
known to bind to the Aβ peptide associated with Alzheimer’s disease [58, 59], β2microglobulin which forms insoluble deposits in dialysis related amyloidosis [60],
and prion protein associated with plaques in Creutzfeldt-Jakob disease [61].
2.2.1 In Vitro Chaperone Activity
α2M forms stable complexes with misfolded proteins to inhibit their stressinduced aggregation and precipitation but is unable to independently promote their
refolding [62]. In addition, depletion of α2M from whole human plasma renders
proteins in this fluid more susceptible to aggregation and precipitation, even at 37
°C [62]. The formation of complexes between α2M and misfolded proteins is
thought to be, at least in part, due to hydrophobic interactions [62]. The binding of
a misfolded substrate protein does not activate α2M and as a result the complex
formed is not bound by LRP. However, while complexed with misfolded client
proteins, α2M remains able to interact with proteases and subsequently adopt its
activated conformation and then interact with LRP [62]. Although LRP is the only
known receptor for α2M, it remains possible that non-activated α2M/misfolded
client protein complexes are taken up via other cell surface receptors. As an example, scavenger receptors have been shown to bind to methylamine activated
forms of α2M [143]. In addition to inhibiting amorphous aggregation, α2M has
been shown to inhibit amyloid fibril formation. This effect can be seen even at
sub-stoichiometric levels of α2M (as low as a 1:100 molar ratio of α2M:substrate)
[144, 145]. It is thought that α2M interacts with lowly populated oligomeric species affecting the formation of stable nuclei from which amyloid formation proceeds [58, 145].
α2M–client protein complexes are thought to be removed from the extracellular
space by receptor mediated endocytosis. α2M-Aβ complexes are internalized via
LRP expressed on U87 cells and are subsequently degraded [58]. In addition,
complexes formed from α2M and heat-stressed citrate synthase (or glutathione-Stransferase, GST) that have been incubated with trypsin also bind to LRP on the
surface of JEG-3 cells [62]. This uptake of complexes may protect cells from the
toxicity of aggregating species. However, under certain conditions, α2M was
shown to promote the neurotoxicity of Aβ [63]. In stark contrast, using primary rat
mixed neuronal cultures, others have demonstrated that α2M can protect cells
from Aβ toxicity [146]. The different effects observed may be explained by differences between systems in the extent of receptor mediated removal of complexes
from the extracellular environment. This is illustrated by the demonstration that in
the presence of α2M (but not otherwise), SH-SY5Y cells expressing the α2M receptor (LRP) are more resistant to Aβ toxicity than cells that do not [63]. The protective effect of α2M could be inhibited by RAP (a pan-specific inhibitor of LRP
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ligand binding). Furthermore, α2M promoted Aβ toxicity against LRP-negative
LAN5 cells but had the opposite effect with LRP-expressing LAN5 transfectants
[63]. Importantly, this function has been demonstrated in vivo: the normally rapid
removal of radiolabelled Aβ from mouse brain is significantly inhibited by the
LDL family inhibitor RAP and antibodies against LRP-1 and α2M.
2.2.2 Evidence for In Vivo Chaperone Action/Disease Involvement
α2M has been found co-localized with Aβ and prion plaques in Alzheimer’s
disease and CJD respectively [61, 63]. In addition, levels of circulating complexes
formed between α2M and β2m in plasma of haemodialysis patients are correlated
with the severity of dialysis related amyloidosis [60]. In addition, α2M has been
found in complex with prion protein in human plasma [64]. Lastly, the ability of
α2M to promote the removal of Aβ from the extracellular space has been shown in
vivo; the normally rapid removal of radiolabelled Aβ from mouse brain is significantly inhibited by the LDL family inhibitor RAP and antibodies against LRP-1
and α2M [147].
2.2.3 Potential Application of α2M in Anti-Cancer Treatments
α2M shares a common receptor (α2M receptor/ LRP1) with a variety of intracellular chaperones [148-150] which have been implicated in the re-presentation
of chaperoned peptides to stimulate an immune response [8, 14, 16, 18-21, 148,
150-154]. This has led to the ability of α2M to perform a similar immunological
function being examined. It was shown that α2M-peptide complexes are able to
induce the re-presentation of the chaperoned peptides on MHC class I molecules
in vitro and subsequently prime a cytotoxic T lymphocyte response in α2Mpeptide immunized mice [55]. As both intra- and extracellular chaperones have
now both been shown to elicit such a response, it has been proposed that α2M
samples the extracellular space and Hsps the intracellular milieu. In this model,
LRP1 facilitates the sampling of the entire antigenic milieu of an organism [55].
Unlike Hsps which are ubiquitously expressed, many tumors do not express α2M.
Thus, in order to explore the use of α2M-peptide complexes as an anti-cancer
treatment, exogenous α2M has been added to tumor cell lysates to generate the
complexes [65]. α2M-peptide complexes made in vitro induced anti-tumor responses and protection against tumor challenge similar to that of GP96 [155].
Thus, α2M and perhaps the other extracellular chaperones all offer potential vehicles for peptide-specific control of the immune response and immune modulatory
therapies.
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2.3 Haptoglobin
Haptoglobin is a secreted glycoprotein with many known biological functions,
however, it is best known as a hemoglobin binding protein. The non-covalent interaction between haptoglobin and hemoglobin is particularly strong with a reported Kd ~ 10-15 M [66]. This interaction prevents the loss of hemoglobin and iron via
glomerular filtration by redirecting the haptoglobin-hemoglobin complex to the
liver [156]. The interaction of haptoglobin with hemoglobin also reduces the
amount of free hemoglobin and iron available to catalyse oxidation reactions
[157], and has an inhibitory effect on nitric oxide [158] and prostaglandin synthesis [159]. Haptoglobin also has a bacteriostatic effect on organisms unable to obtain heme from the hemoglobin-haptoglobin complex [160] and appears to play an
important role in angiogenesis [161]. Finally, haptoglobin has been implicated in
the regulation of lymphocyte transformation [162]. Haptoglobin is found in most
body fluids. Its plasma concentration is between 0.3-2 mg/ml [67] and it is found
in CSF between 0.5-2 µg/ml [66]. Sequence analysis has identified haptoglobin as
a chymotrypsinogen-like serine protease homolog, although it has a distinct biological function [163]. Humans express one of three different haptoglobin phenotypes (Hp 1-1, Hp 1-2 or Hp 2-2) depending on the presence of two principal alleles (Hp1 and Hp2) coding for the α and β chains which associate covalently via
disulphide linkage. The α1, α2 and β chain peptides are 9.2 kDa, 15.9 kDa and
27.2 kDa, respectively [68]. Similar to clusterin, haptoglobin is heavily glycosylated.

2.3.1 In Vitro Chaperone activity
Human haptoglobin specifically inhibits the precipitation of a wide variety of
proteins induced by heat or oxidative stress [68, 69]. All three human haptoglobin
phenotypes exert this chaperone action, although Hp1-1 appears to be the most efficient. Like clusterin, haptoglobin forms stable, soluble high molecular weight
complexes with partially unfolded clients in an ATP-independent manner, but has
no independent refolding activity. The possibility that haptoglobin holds
misfolded proteins in a state competent for refolding by other chaperones is currently untested. Immunoaffinity depletion of haptoglobin from human serum significantly increases the amount of protein that precipitated in response to stresses
[164]. At substoichiometric levels, haptoglobin has been shown to dosedependently inhibit amyloid formation by Aβ, ccβw, calcitonin, and the lysozyme
variant I59T [164].
Haptoglobin is a known ligand of the CD11b/CD18 receptor on natural killer
cells [145]. With much lower affinity, haptoglobin also binds to CD4 and CD8 receptors on T lymphocytes [165]. Neutrophils and monocytes also possess binding
sites for haptoglobin and are responsible for haptoglobin uptake in peripheral
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blood [165]. Additionally, the acute-phase macrophage protein CD163 has been
identified as a scavenger receptor for hemoglobin-haptoglobin complexes [166].
This high affinity receptor ligand interaction is Ca2+-dependent and mediates endocytosis of the hemoglobin-haptoglobin complex [70]. It is possible that
haptoglobin may facilitate the clearance of misfolded proteins via a similar mechanism to the clearance of hemoglobin-haptoglobin complexes, although this is yet
to be investigated.
2.3.2 Evidence for In Vivo Chaperone Action/Disease Involvement
Haptoglobin is upregulated during a variety of conditions including infection,
neoplasia, pregnancy, trauma, acute myocardial infarction and other inflammatory
conditions [70]. Its possible chaperone role in vivo is supported by co-deposition
with amyloid in senile plaques [71], with drusen in age-related macular degeneration [72], and in protein deposits resulting from chronic glomerulonephritis [73].
Surprisingly, haptoglobin gene knockout does not impair the clearance of free
plasma hemoglobin, however haptoglobin-null mice display reduced postnatal viability and greater oxidative damage after induced hemolysis [74].
2.4 ApoE
Apolipoprotein E (ApoE), is a 35 kDa secreted glycoprotein, synthesized primarily by the liver, but can be found expressed by astrocytes, microglia and
oligodendrocytes in the brain. It exists in three isoforms, E2, E3, and E4, which
differ only by single amino acid variations. The prevalence of the alleles coding
for these isoforms, E2, E3 and E4, is approximately 7–8%, 75–80% and 14–15%,
respectively [167, 168]. ApoE is an amphipathic protein that is known for its ability to mediate transport and clearance of cholesterol, triglycerides and other lipids
[169]. It mediates lipid transport through binding to the low density lipoprotein
(LDL) receptor. ApoE is best known for its association with Alzheimer’s disease;
APOE ε4/ε4 homozygotic individuals have a significantly greater risk of developing Alzheimer’s disease [170].
2.4.1 In Vitro Chaperone activity
ApoE has been shown to have the ability to bind to aggregation prone polypeptides, such as tau and Aβ [77, 78]. Interestingly, binding of ApoE to Aβ is isoform-dependent with the binding of ApoE4 being of lowest affinity (E2>E3>E4)
[78, 171]. The stoichiometry of the interaction between Aβ and ApoE has been estimated at 5 Aβ peptide molecules per ApoE molecule [172]. This interaction is
likely to be the driving force behind the ability of ApoE to affect the aggregation
of Aβ. It has been shown to both promote and inhibit Aβ aggregation depending
on the conditions and specific variant of Aβ peptide used. The formation of complexes between ApoE and Aβ1-40 has been shown to inhibit the formation of amy-
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loid, at a 100:1 molar ratio of Aβ:ApoE [173]. The complexes made were added to
monomeric Aβ and were unable to act as “seeds” for amyloid formation. However, the complexes formed still reacted with thioflavin T [173]. In addition, it has
been shown that ApoE can prolong the lag phase of Aβ aggregation without affecting the amount of fibrillar material finally formed [174]. Similarly, ApoE
lengthens the lag phase of amyloid formation from Aβ 29-40 and Aβ29-42 by forming
complexes with the respective peptides [172]. Interestingly, the E4 isotype had no
effect on the lag phase. In contrast, there are many reports that suggest that ApoE
can promote the formation of Aβ fibrils. ApoE was shown to enhance the formation of thioflavin T positive material from Aβ1-40 [175], and promoted fibril
formation by Aβ1-42 (as judged by thioflavin T and transmission electron microscopy) [176].
2.4.2 Evidence for In Vivo Chaperone Action/Disease Involvement
The major focus on ApoE work has been its role in chaperoning Aβ due to its
strong genetic association with Alzheimer’s disease [79]. In humans ApoE has
been found co-localized with Alzheimer’s and CJD plaques [80]. To further complicate understanding of the role of ApoE in amyloid formation (see above),
mouse studies have been similarly conflicting. In initial studies, both Aβ immunoreactivity and amyloid formation were reduced in ApoE knockout mice [177,
178]. In contrast, expression of human ApoE in transgenic mice suppressed Aβ
deposition [179]. Regardless of its effect on amyloid formation, just as observed
for other extracellular chaperones such as clusterin and α2M, complexes formed
between ApoE and Aβ are efficiently taken up by receptor mediated endocytosis
and promote subsequent degradation of Aβ. It has been shown that Aβ-ApoE
complexes bind to the cell surface receptor megalin while free Aβ does not [180].
In addition, LRP1 binds to Aβ-ApoE complexes and internalizes them for subsequent degradation in lysosomes (or transport into plasma) [147]. Furthermore, it
has been suggested that ApoE facilitates internalization and degradation of Aβ by
astrocytes [81]. As Aβ is known to activate glial cells, its incorporation into complexes and its ApoE-dependant receptor mediated uptake may play a role in modulating the immune response. Consistent with this idea, it has been shown that the
formation of ApoE- Aβ complexes inhibits the activation of astroctyes by Aβ
[181].
2.5 Serum Amyloid P Component
Serum Amyloid P Component (SAP) is a member of the highly conserved
pentraxin family and consists of five identical 25 kDa subunits arranged in a ring
[182]. As for other pentraxins, SAP displays calcium-dependent ligand binding
and tertiary structure similar to legume lectins [183]. It is estimated that over 8%
of the mass of the molecule is N-linked oligosaccharide [183]. It has been proposed that SAP circulates as a decamer with two pentameric rings noncovalently
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bound [183, 184]. However, other reports claim that SAP exists as a single
pentamer in the body and that the decameric form is obtained only upon purification [185, 186]. Human SAP shares approximately 51% amino acid homology
with C-reactive protein, a classical human acute phase protein. In contrast, SAP
does not behave as an acute phase protein in humans [82]; it is generally present in
human plasma at around 40 µg/ml [83] and in CSF at around 8.5 ng/ml [84]. Although to date no clear biological function has been ascribed to SAP, it is known to
interact with a diverse range of molecules in vitro. For example, SAP binds to
glycosaminoglycans [187], DNA and chromatin [188-190], complement components [191, 192], fibronectin [193], C-reactive protein [194], aggregated IgG
[195], phosphatidylethanolamine [196] and endotoxin [183, 197]. Of particular interest in the current context, SAP binds highly specifically to amyloid and is universally found in amyloid deposits [85-88, 191].
2.5.1 In Vitro Chaperone Activity
There is currently little evidence for the existence of efficient refolding chaperones in the extracellular milieu, however, it has been reported that SAP has ATPindependent refolding activity [89]. When present at a 10-fold molar excess, SAP
was able to recover 25% of the initial enzyme activity of denatured lactate dehydrogenase. Whether this activity would be enhanced by the presence of ATP or
“helper” chaperones is currently unknown. Further studies are needed before the
potential physiological significance of this refolding activity becomes clear. SAP
binds to synthetic Aβ at physiological concentrations of Ca2+ [198] and binds to
all types of amyloid fibrils tested in vitro [199]. SAP has a protease-resistant βpleated sheet structure that in the presence of Ca2+ is resistant to proteolysis [200].
Consequently, SAP binding to amyloid fibrils is thought to inhibit their proteolytic
digestion.
2.5.2 Evidence for In Vivo Chaperone Action/Disease Involvement
SAP constitutes up to 15% of the mass of amyloid deposits in vivo, which is
remarkable considering it is only present in plasma at trace concentrations. Also,
strongly supporting a role for SAP in amyloid pathogenesis is the frequency with
which it is found localized in amyloid deposits in vivo [85-88, 90]. SAP knockout
mice are viable and fertile with no obvious abnormalities, however, they display
delayed amyloid deposition in models of systemic amyloidosis [89]. These results
support that SAP plays a role in amyloid pathogenesis and that inhibition of SAP
binding to amyloid is a potential therapeutic target. Given that SAP does not appear to be expressed in the brain, localization of SAP with cerebral amyloid deposits suggest that either specific active transport mechanisms exist to transport it
from one side of the blood-brain barrier to the other or that damage to the bloodbrain barrier is sufficient to allow the protein to leak into the brain during disease.
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Regardless of the mechanism by which it gets there, the CSF concentration of
SAP is higher in patients with Alzheimer’s disease [85].
2.6 Caseins
Casein is the main constituent of milk (~ 80% of protein in bovine milk) and is
made up of a heterogeneous mixture of phosphoproteins that includes four unrelated gene products, αS1-, αS2-, β- and κ-casein. In their monomeric forms, the caseins themselves are small, ranging in molecular mass between 19 and 25 kDa.
However, the casein proteins exhibit a strong tendency to associate with each other, through hydrophobic and ionic interactions, which, in the presence of calcium
and other ions, leads to the formation of casein micelles [91]. The micelles range
in mass between 103 and 3 x 106 kDa and represent the primary nutritional source
of calcium (in the form of calcium phosphate) to the neonate [91]. The caseins
have been classified as intrinsically disordered proteins, as they are extremely
flexible, essentially unfolded and have relatively little secondary or tertiary structure under physiological conditions [201]. Their open, dynamic and malleable
conformations suggest that they exist in a molten globule-like state, with extensive
regions of solvent-exposed and clustered hydrophobicity [202]. As a result, it is
unlikely that detailed X-ray crystal structures of full-length casein protein will be
achieved; however, three-dimensional energy-minimized molecular models are
available [203, 204]. Two of the casein proteins, αS1- and β-casein, have been
found to have molecular chaperone-like activity, similar to the small heat shock
proteins (sHsps) [26, 92]. The open, flexible nature of αS1-casein and β-casein results from the high percentage of proline residues in their amino acid sequence
(9% of the amino acid sequence of αS1-casein and 18% of β-casein) and lack of
disulfide bonds. Both αS1-casein and β-casein also possess a high degree of overall
hydrophobicity, with well separated hydrophilic and hydrophobic domains. Such
properties, which they share with other molecular chaperones such as the sHsps
and clusterin [26], likely accounts for their ability to bind to a wide-range of destabilized, partially unfolded target proteins to prevent their aggregation [92].
2.6.1 In Vitro Chaperone Activity
To date, studies on the chaperone-like activity of casein proteins have been performed with bovine whole casein (comprising all four casein proteins) or with αScasein (comprising both αS1- and αS2-casein) or β-casein. Thus, αS-casein and βcasein have been shown to inhibit the amorphous aggregation of a range of unrelated target proteins induced by heating [93-97], reduction [93, 95, 96] and UVlight [93]. They do so by forming high molecular weight complexes with the target protein, and stabilizing them in order to prevent their aggregation and potential
precipitation. They have no intrinsic re-folding ability [95, 96] and thus their
mechanism of action is akin to the sHsps and clusterin [26]. The chaperone-like
activity of αS-casein and β-casein against amorphously aggregating target proteins
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is phosphorylation-dependent, dephosphorylation decreasing their chaperone efficacy [94, 205]. The caseins are heavily phosphorylated (typically 8 phosphate residues per mole for αS1-casein and 5 for β-casein) which, apart from its role in calcium-binding and stabilization of the casein micelle, appears to play a significant
role (via their negative charge) in maintaining the solubility of the complexes
formed between the caseins and target proteins [205]. It has recently been suggested that the chaperone-like activity of these caseins may be exploited in order
to control protein aggregation during food production [92]. αS-casein and β-casein
also appear to possess a generic ability to prevent protein aggregation associated
with fibril formation. For example, whole and β-casein inhibit heat-induced fibril
formation by ovalbumin [206], αS-casein and β-casein inhibit κ-casein fibril formation [205, 207], and αS1-casein inhibits αS2-fibril formation [208].
2.6.2 Evidence for In Vivo Chaperone Action/Disease Involvement
Caseins are uniquely synthesized in the mammary gland and immediately
associate to form casein micelles, which are secreted into the alveolar lumen
[209]. There is no direct evidence that a failure in the chaperone action of αScasein and β-casein is involved in disease, however, amyloid-like deposits
(known as corpora amylacea) have been identified in mammary tissue from a
variety of species [98-100], and bundles of fibrils have been reported in the
cytoplasm of cells that surround these calcified deposits [101]. The proteins
present in these deposits and fibrils include the caseins [102, 103]. When isolated from the other caseins, αS2- and κ-casein readily form fibrils when incubated under conditions of physiological pH and temperature (i.e. pH 7.0-7.4,
37 °C) [207, 208, 210, 211] which suggests that these proteins may form fibrils in vivo. However, fibril formation by αS2- and κ-casein is inhibited by
physiological concentrations of αS1- and β-casein in vitro [207, 208] and thus,
the tendency of caseins to associate together acts as a protective mechanism
to prevent this form of aggregation. Indeed, the fact that amyloid deposits in
mammary tissue are not more prevalent is most likely attributable to the
chaperone-like ability of αS1- and β-casein, which act to prevent the release of
the amyloidogenic αS2- and κ-casein precursors by binding them into casein
micelles.
2.7 Fibrinogen
Fibrinogen is synthesized by the liver and circulates in human plasma at a concentration of 2-4.5 mg/ml [212]. It is the 340 kDa glycoprotein precursor to fibrin,
which forms clots in the wound response. Fibrinogen is an “acute phase protein”
and its levels in plasma are elevated in response to a variety of stresses including
stroke, atherosclerotic diseases, age and acute myocardial infarction [212]. Fibrinogen molecules are comprised of two sets of disulfide-linked Aα-, Bβ-, and γchains. Fibrin is formed after cleavage of fibrinopeptide A (FPA) from fibrinogen
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Aα-chains, which initiates fibrin polymerization. In addition to its well known
role in providing a scaffold for clots, fibrinogen also has other biological functions
involving a range of binding sites, some of which are only exposed as a consequence of fibrin formation. These other functions include recruiting platelets into
clots, down-regulation of circulating levels of thrombin, and plasminogen activation [212].
2.7.1 In Vitro Chaperone Activity
Two publications only have appeared so far describing the chaperone activity
of fibrinogen. The first of these presented results suggesting that human plasma
fibrinogen (i) specifically, and independently of ATP, inhibited the thermally induced aggregation of citrate synthase and firefly luciferase, (ii) held the heatstressed forms of these proteins in a state competent for refolding by a rabbit reticulocyte lysate, (iii) inhibited amyloid formation by yeast prion protein Sup35,
and (iv) inhibited heat-induced aggregation of proteins in undiluted mouse plasma
[105]. These studies were described as having been done using fibrinogen sourced
from a commercial supplier (which would be expected to be overwhelmingly
comprised of the usual 340 kDa form). However, in a subsequent study by the
same group, similar chaperone properties were attributed specifically to the αEC
C-terminal extension of fibrinogen, present only in a much less abundant 420 kDa
isoform of the protein (fibrinogen-420) [106]. Fibrinogen-420 is normally present
in human plasma at 20-150 mg/ml (i.e. making up about 0.4-7.5% of the circulating fibrinogen pool). Our own experiments failed to show any chaperone activity
for the 340 kDa form of fibrinogen (A. Wyatt, unpublished). The reason(s) for the
apparent discrepancy between these two publications is unclear. However, the balance of evidence suggests that the abundant 340 kDa form of fibrinogen is not a
chaperone, but that the αEC moiety in fibrinogen-420 is a chaperone-active species.
2.7.2 Evidence for In Vivo Chaperone Action/Disease Involvement
The level of αEC can be regulated by proteases (such as matrix
metalloproteases and plasmin) which can rapidly release it from fibrinogen-420. It
has been suggested that fibrinogen-420 acts as a delivery vehicle for αEC [106].
Evidence for an in vivo chaperone role for fibrinogen-420/αEC is currently limited
to the demonstration that (i) proteins in plasma of fibrinogen knock-out mice aggregate to a greater extent when incubated for 48 h at 43 °C than those in the
plasma of wild-type mice [106], and (ii) exogenously added αEC formed complexes with a variety of proteins in human plasma heated for 30 min at 50 °C
[106]. Future work will hopefully further define the in vivo role(s) of the fibrinogen-420/αEC chaperone activity and its potential involvement in diseases.
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2.9 In Vivo Functions of Extracellular Chaperones
It is clear from the growing number of abundant ECs identified that they are
likely to play very important roles in the maintenance of normal physiological
functions. The precise details of these roles are currently under investigation but
are likely to include (i) selective binding to exposed regions of hydrophobicity on
extracellular proteins induced to misfold by (for example) various physical or
chemical stresses, leading to (ii) inhibition of their toxicity towards cells and (iii)
stabilization of their structure so that they are prevented from aggregating to form
insoluble deposits. Soluble complexes formed between ECs and misfolded proteins are probably internalized via receptor-mediated endocytosis and subsequently degraded by (for example) lysosomal proteolysis. However, it is also feasible
that within antigen-presenting cells ECs can direct bound protein antigens to other
intracellular proteolytic systems such as the proteasome, and that peptide fragments of the degraded chaperone client proteins are later presented at the cell surface in association with Class I and/or II major histocompatibility antigens. In this
way, ECs may play multiple critical roles in vivo, protecting the body from the
dangers of inappropriate aggregation of extracellular proteins but also playing a
pivotal role in the processing of extracellular protein antigens necessary for eliciting protective immune responses (Figure 1).

3 Conclusions
It is barely over a decade since the first abundant mammalian extracellular
chaperone (clusterin) was identified. Since that time there have been a series of
discoveries of other extracellular chaperones such that we now know there are at
least 7 present at (in some cases) substantial concentrations in human blood. Collectively, by mass, these chaperones account for possibly in excess of 7% of all
blood proteins. The caseins are also abundant in another important extracellular
fluid, milk. It will be unsurprising if further extracellular chaperones are identified
in coming years. The shear abundance of these chaperones in body fluids strongly
suggests that they perform vital biological functions. These functions may include
roles in stabilizing misfolded proteins aggregating via either the amorphous or
amyloid-forming pathways, mediating the clearance of these aggregation-prone
(and often toxic) proteins from the body, and modulating the response of the immune system to extracellular antigens. The processes governing the development
of the many serious human diseases linked to inappropriate aggregation of extracellular proteins are poorly understood. Clearly, advances in knowledge of extracellular chaperones will impact upon our ability to prevent and treat these diseases, and may allow us to better harness the power of the immune system to fight
conditions such as cancers. Furthermore, extracellular chaperones may exert powerful but currently poorly characterized effects on the delivery and efficacy of systemically administered hydrophobic drugs. All of these considerations point to the
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importance of future work to identify the in vivo roles of the growing family of extracellular chaperones.
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Figure legend
Figure 1 Theoretical model for the involvement of ECs in extracellular
proteostasis and the immune response. Under normal physiological conditions
misfolded extracellular proteins are bound by (a) scavenger-like receptors directly,
or (b) circulating ECs, keeping them soluble and facilitating their subsequent
transport to cell surface scavenger-like receptors. EC-client protein complexes
may internalized and subsequently degraded by lysosomal proteolysis. Alternatively, on antigen presenting cells (c), EC (or IC)-client protein complexes may be
(i) bound and internalized by a variety of receptors, (ii) subsequently processed
intracellularly by yet to be established mechanisms, and then (iii) re-presented as
peptides on the cell surface associated with major histocompatibility (MHC) antigen class I or II molecules to trigger the release of cytokines and an immune response.
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